CoChat
Sign Up
Cited by 4Frailty in Older AdultsCancer Immunotherapy and BiomarkersNutrition and Health in Aging

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Anti-Cancer Treatment Strategies in the Older Population: Time to Test More?

Open access
Tralongo, Antonino C., Fratamico, Roberto S., Russo, Chiara, Sbrana, Andrea, Antonuzzo, Andrea, Danova, Marco·2021·Geriatrics
DOI 10.3390/geriatrics6020042PMC PMC8167638
Open this paper in CoChat — free accountOpen PDF

Abstract

Aging is a well-recognized risk factor for the development of cancer. The incidence of new cancer diagnoses has increased globally given the rising senior population. Many hypotheses for this increased risk have been postulated over decades, including increased genetic and epigenetic mutations and the concept of immunosenescence. The optimal treatment strategies for this population with cancer are unclear. Older cancer patients are traditionally under-represented in clinical trials developed to set the standard of care, leading to undertreatment or increased toxicity. With this background, it is crucial to investigate new opportunities that belong to the most recent findings of an anti-cancer agent, such as immune-checkpoint inhibitors, to manage these daily clinical issues and eventually combine them with alternative administration strategies of antiblastic drugs such as metronomic chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/geriatrics6020042

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 55

  1. Hutchins, 1999, Underrepresentation of patients 65 years of age or older in cancer-treatment trials, N. Engl. J. Med., 341, 2061, 10.1056/NEJM199912303412706 · DOI
  2. Pang, 2016, Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012, J. Clin. Oncol., 34, 3992, 10.1200/JCO.2016.67.7088 · DOI
  3. Freedman, 2017, Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527, J. Clin. Oncol., 35, 421, 10.1200/JCO.2016.69.4182 · DOI
  4. DeSantis, 2019, Cancer statistics for adults aged 85 years and older, 2019, CA Cancer J. Clin., 69, 452, 10.3322/caac.21577 · DOI · Paper page
  5. Ries, E.M., Kosary, C.L., and Hankey, B.F. (2003). SEER Cancer Statistic Review 1975–2000.
  6. Sant, 2014, Cancer survival in Europe 1999–2007 by country and age: Results of EUROCARE--5-a population-based study, Lancet Oncol., 15, 23, 10.1016/S1470-2045(13)70546-1 · DOI
  7. Niccoli, 2012, Ageing as a risk factor for disease, Curr. Biol., 22, R741, 10.1016/j.cub.2012.07.024 · DOI · Paper page
  8. Sandiford, 2018, Human Aging and Cancer: Role of miRNA in Tumor Microenvironment, Adv. Exp. Med. Biol., 1056, 137, 10.1007/978-3-319-74470-4_9 · DOI
  9. Falandry, 2014, Biology of Cancer and Aging: A Complex Association With Cellular Senescence, J. Clin. Oncol., 32, 2604, 10.1200/JCO.2014.55.1432 · DOI
  10. Aunan, 2017, The Biology of Aging and Cancer: A Brief Overview of Shared and Divergent Molecular Hallmarks, Aging Dis., 8, 628, 10.14336/AD.2017.0103 · DOI
  11. Pawelec, 2017, Immunosenescence and cancer, Biogerontology, 18, 717, 10.1007/s10522-017-9682-z · DOI · Paper page
  12. Ikuno, 1995, Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum, J. Natl. Cancer Inst., 87, 1876, 10.1093/jnci/87.24.1876 · DOI
  13. Tralongo, 2020, Management of chemotherapy-induced neutropenia in patients with cancer: 2019 guidelines of the Italian Medical Oncology Association (AIOM), Tumori, 106, 273, 10.1177/0300891620927093 · DOI
  14. Losonczy, 2012, Supportive care during chemotherapy for lung cancer in daily practice, Magy Onkol., 56, 159
  15. Sawhney, 2005, Physiologic aspects of aging: Impact on cancer management and decision making, part I, Cancer J., 11, 449, 10.1097/00130404-200511000-00004 · DOI
  16. Sehl, 2005, Physiologic aspects of aging: Impact on cancer management and decision making, part II, Cancer J., 11, 461, 10.1097/00130404-200511000-00005 · DOI
  17. Zocchi, 2004, Role of gammadelta T lymphocytes in tumor defense, Front Biosci., 9, 2588, 10.2741/1419 · DOI
  18. Yancik, 1998, Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: A population-based study, Cancer, 82, 2123, 10.1002/(SICI)1097-0142(19980601)82:11<2123::AID-CNCR6>3.0.CO;2-W · DOI
  19. Lindner, 2014, A meta-analysis of cognitive impairment following adult cancer chemotherapy, Neuropsychology, 28, 726, 10.1037/neu0000064 · DOI
  20. Extermann, 2012, Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score, Cancer, 118, 3377, 10.1002/cncr.26646 · DOI
  21. Kotzerke, 2019, The performance of three oncogeriatric screening tools—G8, optimised G8 and CARG—In predicting chemotherapy-related toxicity in older patients with cancer. A prospective clinical study, J. Geriatr. Oncol., 10, 937, 10.1016/j.jgo.2019.04.004 · DOI
  22. Moth, 2019, Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG Toxicity Score with oncologists’ estimates of toxicity based on clinical judgement, J. Geriatr. Oncol., 10, 202, 10.1016/j.jgo.2018.08.010 · DOI
  23. Browder, 2000, Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer, Cancer Res., 60, 1878
  24. Cazzaniga, 2017, Metronomic chemotherapy for advanced breast cancer patients, Cancer Lett., 400, 252, 10.1016/j.canlet.2016.12.019 · DOI
  25. Benevento, 2017, Metronomic chemotherapy in head and neck cancer, Cancer Lett., 400, 219, 10.1016/j.canlet.2016.10.047 · DOI
  26. Filippi, 2018, Rationale for the use of metronomic chemotherapy in gastrointestinal cancer, Expert Opin. Pharmacother., 19, 1451, 10.1080/14656566.2018.1512585 · DOI
  27. Woo, 2017, Metronomic chemotherapy in metastatic colorectal cancer, Cancer Lett., 400, 319, 10.1016/j.canlet.2017.02.034 · DOI
  28. Bergers, 2003, Tumorigenesis and the angiogenic switch, Nat. Rev. Cancer, 3, 401, 10.1038/nrc1093 · DOI · Paper page
  29. Carmeliet, 2000, Angiogenesis in cancer and other diseases, Nature, 407, 249, 10.1038/35025220 · DOI · Paper page
  30. Bocci, 2002, Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs, Cancer Res., 62, 6938
  31. Klement, 2002, Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts, Clin. Cancer Res., 8, 221
  32. Hanahan, 2011, Hallmarks of cancer: The next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  33. Yamaguchi, 2006, Regulatory T cells in immune surveillance and treatment of cancer, Semin. Cancer Biol., 16, 115, 10.1016/j.semcancer.2005.11.005 · DOI
  34. Sinha, 2009, Myeloid-derived suppressor cells: Linking inflammation and cancer, J. Immunol., 182, 4499, 10.4049/jimmunol.0802740 · DOI
  35. Bryniarski, 2009, Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice, Pharmacol. Rep., 61, 550, 10.1016/S1734-1140(09)70098-2 · DOI
  36. Ghiringhelli, 2007, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients, Cancer Immunol. Immunother., 56, 641, 10.1007/s00262-006-0225-8 · DOI
  37. Kaneno, 2009, Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations, J. Transl. Med., 7, 58, 10.1186/1479-5876-7-58 · DOI
  38. Mencoboni, 2017, Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC, Anticancer Res., 37, 3189
  39. Cazzaniga, 2017, La chemioterapia metronomica nelle pazienti anziane con carcinoma mammario avanzato: È l’inizio di una nuova era?, Arg. Geriat. Oncol., 2, 13
  40. Coley, 1991, The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893, Clin. Orthop. Relat. Res., 262, 3
  41. Hierro, 2017, The expanding role of immunotherapy, Cancer Treat. Rev., 54, 74, 10.1016/j.ctrv.2017.01.008 · DOI
  42. Francisco, 2009, PD-L1 regulates the development, maintenance, and function of induced regulatory T cells, J. Exp. Med., 206, 3015, 10.1084/jem.20090847 · DOI
  43. Amarnath, 2011, The PDL1-PD1 axis converts human TH1 cells into regulatory T cells, Sci. Transl. Med., 3, 111ra120, 10.1126/scitranslmed.3003130 · DOI
  44. Chambers, 1997, Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells, Immunity, 7, 885, 10.1016/S1074-7613(00)80406-9 · DOI
  45. Robert, 2019, Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study, Lancet Oncol., 20, 1239, 10.1016/S1470-2045(19)30388-2 · DOI · Paper page
  46. Motzer, 2018, Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N. Engl. J. Med., 378, 1277, 10.1056/NEJMoa1712126 · DOI · Paper page
  47. Hanna, 2020, Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update, J. Clin. Oncol., 38, 1608, 10.1200/JCO.19.03022 · DOI
  48. Schmid, 2018, Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer, N. Engl. J. Med., 379, 2108, 10.1056/NEJMoa1809615 · DOI · Paper page
  49. Elias, 2018, Efficacy of PD-1 & PD-L1 inhibitors in older adults: A meta-analysis, J. Immunother. Cancer, 6, 26, 10.1186/s40425-018-0336-8 · DOI · Paper page
  50. Ciccarese, 2020, The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients’ Age: A Systematic Review and Meta-Analysis, J. Immunother., 43, 95, 10.1097/CJI.0000000000000312 · DOI
  51. Xu, 2017, Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models, Clin. Cancer Res., 23, 5869, 10.1158/1078-0432.CCR-17-0483 · DOI
  52. Kareva, I. (2017). A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells. Int. J. Mol. Sci., 18. · DOI
  53. Ellebaek, 2012, Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: Results from a phase II trial, Cancer Immunol. Immunother., 61, 1791, 10.1007/s00262-012-1242-4 · DOI
  54. Karachi, 2019, Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition, Neuro Oncol., 21, 730, 10.1093/neuonc/noz015 · DOI
  55. Chang, 2015, Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression, Cell, 162, 1229, 10.1016/j.cell.2015.08.016 · DOI · Paper page

Cited by

Sorted by citations

See all 4

Metadata

Authors
Tralongo, A. C., Fratamico, R. S., Russo, C., Sbrana, A., Antonuzzo, A., & Danova, M.
Affiliations
  • University of Pavia (IT)
  • John and Dorothy Morgan Cancer Center, Lehigh Valley Cancer Institute, Allentown, PA 18103, USA
  • Centre Léon Bérard (FR)
  • Azienda Ospedaliera Universitaria Pisana (IT)
  • Azienda Socio Sanitaria Territoriale di Pavia (IT)
Corresponding author
Tralongo, Antonino C.
ORCID
Venue
Geriatrics
Publisher
MDPI AG
Published
2021-04-15
Volume
6
Issue
2
Pages
42
ISSN
2308-3417 (ISSN-L)
DOI
10.3390/geriatrics6020042
PMC
PMC8167638
OpenAlex
W3156741860
Cited by
4
References
1
Citations by year
2025: 2 · 2024: 1 · 2022: 1
FWCI
0.28
Type
journal article
Language
en
Open access
Licence
Locations
  • Geriatrics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Frailty in Older Adults
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
Keywords
geriatric oncology, anticancer treatment, immunosenescence, aging and cancer risk, immune checkpoint inhibitors, metronomic chemotherapy, treatment toxicity, undertreatment, epigenetic mutations

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review